News
NewAmsterdam Pharma Announces Issuance Of Composition Of Matter Patent For Obicetrapib By The USPTO
11 Jun 24
Biotech, News, General
RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
7 Jun 24
News, Price Target, Reiteration, Analyst Ratings
NewAmsterdam Pharma To Present New Analysis From The Phase 2 ROSE2 Trial Evaluating Obicetrapib In Combination With Ezetimibe At 2024 American College Of Cardiology Congress
25 Mar 24
Biotech, News, General
Press releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 Jun 24
Press Releases
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
9 Apr 24
Press Releases
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
9 Apr 24
Press Releases